Affiliation:
1. Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Abstract
Although viral myocarditis has been mostly attributed to enterovirus and adenovirus infection, the importance of hepatitis C virus has recently been noted. Clinical trials of antiviral agents, such as interferons, are in progress, while new therapies such as viral vaccines, recombinant virus and virus receptors, are in preclinical development. Whereas immunosuppression with corticosteroids or cyclosporin is ineffective, immunosuppressors that do not promote viral replication, such as FTY720, and immunomodulation by interleukin-10, are promising new approaches. Inhibition of nuclear factor-κB, angiotensin II and endothelin effectively suppresses inflammation in experimental viral myocarditis. Embryonic stem cell therapy has been demonstrated to be beneficial; however, this requires further investigation.
Subject
Cardiology and Cardiovascular Medicine,Molecular Medicine
Reference65 articles.
1. The challenge of cardiomyopathy
2. INFLAMMATORY HEART DISEASE: Pathogenesis, Clinical Manifestations, and Treatment of Myocarditis
3. MatsumoriA: Introductory chapter. Cardiomyopathies and heart failure. In:Cardiomyopathies and Heart Failure. Matsumori A (Ed.), Kluwer Publishers, Boston, USA,1–15 (2003).
4. MatsumoriA: Animal models: pathological findings and therapeutic considerations. In:Viral Infection of the Heart. Banatvala JE (Ed.), Kent: Edward Arnold, London, UK,110–137 (1993).
5. KimK-S, Höfling K, Carson SD, Chapman NM, Tracy S: The primary viruses of myocarditis. In:Myocarditis. Cooper LT (Ed.), Humana Press, Totowa, USA,23–53 (2003).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献